Versius surgical robot continues to gain traction in the market, with over 30,000 cases completed globally
CMR Surgical has announced a significant milestone, with over 30,000 surgical cases completed worldwide using its Versius surgical robot, solidifying its position as the second-most utilized soft-tissue surgical robot.
Versius Highlights:
- Designed for minimal access surgery, enabling surgeons to access delicate areas like the lungs, thymus, and esophagus.
- FDA-cleared in October 2024, with enhancements such as the Ultrasonic Dissector.
- Features include collaborative arms, 3D HD vision, ergonomic working positions, and easy-to-adopt instrument control.
- Versatile: Used across multiple specialties, including urology, general surgery, gynecology, and thoracic surgery.
With 70% of hospitals using Versius across multiple specialties, the robot’s impact is growing. Additionally, CMR Surgical has ongoing clinical trials for pediatric surgery and transoral robotic surgery (TORS) in the UK.
CEO Massimiliano Colella expressed pride in the milestone, attributing it to the surgeons, hospitals, and employees dedicated to transforming surgery and improving patient outcomes.
Follow MEDWIRE.AI for more updates on advancements in surgical robotics.
